Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
An announcement from Living Cell Technologies ( (AU:1AI) ) is now available.
Algorae Pharmaceuticals has appointed senior industry executive David Gulland as a Non-Executive Director, adding more than 20 years of experience in wholesale pharmaceuticals, private healthcare funding and pharmacy services at a time when the company is rapidly scaling its commercial operations in Australia and New Zealand. Gulland, formerly General Manager of HPS Pharmacies, a division of EBOS Group, brings a track record in digital transformation, supply chain optimisation and innovative funding models such as in-home chemotherapy, which is expected to bolster Algorae’s operational capabilities and market expansion efforts.
In a planned board transition, long-serving Non-Executive Director Bradley Latham will retire from the board but remain as a consultant, creating room for deeper pharmaceutical expertise at governance level. Gulland will also become Chief Operating Officer of AlgoraeRx from 23 March 2026, leading the board to classify his directorship as non‑independent and implement conflict‑management arrangements, underscoring a tighter alignment between board oversight and operational execution as Algorae enters its next growth phase.
The most recent analyst rating on (AU:1AI) stock is a Sell with a A$0.01 price target. To see the full list of analyst forecasts on Living Cell Technologies stock, see the AU:1AI Stock Forecast page.
More about Living Cell Technologies
Algorae Pharmaceuticals Ltd is an Australian pharmaceutical company focused on building a commercial medicines business across Australia and New Zealand. The company operates in wholesale distribution and pharmacy-related services through its subsidiary AlgoraeRx, targeting hospitals and institutional healthcare providers as it scales its presence in the regional pharmaceutical supply chain.
Average Trading Volume: 1,527,039
Technical Sentiment Signal: Sell
Current Market Cap: A$23.98M
See more data about 1AI stock on TipRanks’ Stock Analysis page.